Global management of drug-drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist. [PDF]
Valsecchi AA +16 more
europepmc +1 more source
[[abstract]]Abiraterone acetate and enzalutamide are useand can increase the life span of CRPC patients for a few months. However, approximately 40% of patients do not respond to treatment with enzalutamide or abiraterone and the majority of patients who
Chuu, CP;Lin, TP;Huo, C
core
Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting. [PDF]
Alkan O +3 more
europepmc +1 more source
Redefining the mCRPC frontline: lessons from PEACE-3 and BRCAaway in the post-ARPI era. [PDF]
Banna GL +3 more
europepmc +1 more source
Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review). [PDF]
N S +8 more
europepmc +1 more source
Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. [PDF]
Elsesy ME +17 more
europepmc +1 more source
Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer. [PDF]
Paras G, Schweizer MT.
europepmc +1 more source
Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis. [PDF]
Ma L +6 more
europepmc +1 more source
3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer. [PDF]
Bitaraf M +8 more
europepmc +1 more source

